Traders Buy Shares of Alexion Pharmaceuticals, Inc. (ALXN) on Weakness

Traders bought shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) on weakness during trading on Thursday. $76.23 million flowed into the stock on the tick-up and $63.64 million flowed out of the stock on the tick-down, for a money net flow of $12.59 million into the stock. Of all companies tracked, Alexion Pharmaceuticals had the 16th highest net in-flow for the day. Alexion Pharmaceuticals traded down ($0.01) for the day and closed at $110.33

Several brokerages have issued reports on ALXN. SunTrust Banks, Inc. restated a “buy” rating and issued a $180.00 target price (up from $170.00) on shares of Alexion Pharmaceuticals in a research note on Wednesday, September 13th. Deutsche Bank AG restated a “buy” rating and issued a $158.00 target price (up from $153.00) on shares of Alexion Pharmaceuticals in a research note on Wednesday, September 13th. BMO Capital Markets restated an “outperform” rating and issued a $173.00 target price (up from $168.00) on shares of Alexion Pharmaceuticals in a research note on Wednesday, September 13th. BidaskClub upgraded Alexion Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, July 25th. Finally, Evercore ISI began coverage on Alexion Pharmaceuticals in a research note on Wednesday, August 16th. They issued an “in-line” rating and a $137.00 target price on the stock. Six research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $154.01.

The company has a debt-to-equity ratio of 0.35, a current ratio of 2.96 and a quick ratio of 2.51. The company has a market cap of $24,650.00, a PE ratio of 22.49, a P/E/G ratio of 1.20 and a beta of 1.22.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.44 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.32 by $0.12. Alexion Pharmaceuticals had a return on equity of 12.55% and a net margin of 14.57%. The business had revenue of $859.00 million during the quarter, compared to analysts’ expectations of $864.34 million. During the same period in the previous year, the business earned $1.23 earnings per share. The firm’s revenue was up 7.5% on a year-over-year basis. sell-side analysts anticipate that Alexion Pharmaceuticals, Inc. will post 4.81 earnings per share for the current fiscal year.

In other news, EVP Julie O’neill sold 11,160 shares of the company’s stock in a transaction dated Monday, August 28th. The stock was sold at an average price of $140.00, for a total value of $1,562,400.00. Following the completion of the transaction, the executive vice president now directly owns 26,704 shares in the company, valued at approximately $3,738,560. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Ann M. Veneman sold 835 shares of the company’s stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $145.81, for a total value of $121,751.35. Following the completion of the transaction, the director now owns 5,480 shares of the company’s stock, valued at $799,038.80. The disclosure for this sale can be found here. Insiders sold a total of 16,490 shares of company stock valued at $2,337,251 over the last quarter. Company insiders own 4.35% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the company. Commerzbank Aktiengesellschaft FI boosted its holdings in shares of Alexion Pharmaceuticals by 151.5% in the 2nd quarter. Commerzbank Aktiengesellschaft FI now owns 132,698 shares of the biopharmaceutical company’s stock worth $16,145,000 after purchasing an additional 79,943 shares in the last quarter. HPM Partners LLC boosted its holdings in Alexion Pharmaceuticals by 267.2% during the 2nd quarter. HPM Partners LLC now owns 6,680 shares of the biopharmaceutical company’s stock valued at $656,000 after acquiring an additional 4,861 shares during the period. Assenagon Asset Management S.A. boosted its holdings in Alexion Pharmaceuticals by 4,509.0% during the 3rd quarter. Assenagon Asset Management S.A. now owns 884,150 shares of the biopharmaceutical company’s stock valued at $124,037,000 after acquiring an additional 864,967 shares during the period. Principal Financial Group Inc. boosted its holdings in Alexion Pharmaceuticals by 1.2% during the 2nd quarter. Principal Financial Group Inc. now owns 335,525 shares of the biopharmaceutical company’s stock valued at $40,823,000 after acquiring an additional 4,115 shares during the period. Finally, IFC Holdings Incorporated FL purchased a new stake in Alexion Pharmaceuticals during the 3rd quarter valued at about $861,000. Hedge funds and other institutional investors own 96.71% of the company’s stock.

WARNING: This report was first published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this report on another domain, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this report can be accessed at https://ledgergazette.com/2017/11/18/traders-buy-shares-of-alexion-pharmaceuticals-inc-alxn-on-weakness.html.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply